5 Aggressive Tech Plays Under $10
“These are five stocks for very aggressive investors looking to get share-count leverage with stocks that have sizable upside potential,” declares the author of today’s… Read More »5 Aggressive Tech Plays Under $10
Alex Clarke
These Biotechs Are Awaiting FDA Rulings In December
November saw the FDA grant its first emergency use approval for an at-home, self-collected nasal swab test for COVID-19 and approve the first drugs for… Read More »These Biotechs Are Awaiting FDA Rulings In December
This Under-The-Radar Biotech’s Unique Approach To Drug Development Could Supercharge Your Portfolio
With potential COVID-19 vaccines and therapeutics garnering most of the attention this year in the biotech space, the biotech stock featured in today’s article, which has “a unique approach to the business of drug development” for genetic diseases, has been flying under the radar.
2 Recommendations For Biotech Upside
Hated stocks and biotech are the best bets right now.
“Solid Upside Potential”: 5 Stocks Trading Under $10 For Very Aggressive Investors
“These are five stocks for very aggressive investors looking to get share-count leverage with stocks that have sizable upside potential.”
Upside Potential Over 100% Have Analysts “Pounding The Table” On These 3 Stocks
Among the three stocks highlighted in today’s article where analysts at RBC see upside potential over 100% – and which have all earned “Strong Buy” consensus analyst ratings – is “a pharmaceutical company with a unique niche.
“Explosive Growth Potential”: 2 Under-The-Radar Cancer Drugmakers For Risk-Tolerant Investors
Which developmental-stage biotechs have the potential to beat the difficult odds and successfully get their novel drugs to market?
“The Single Best Investment For The Next Decade”
What is this investment opportunity that seems to check all the boxes?
These 2 Coronavirus Vaccine Stocks Offer “The Best Of Both Worlds”
Of the two “best of both worlds” biotech stocks highlighted in today’s article – “companies with both solid drug-development track records and potential COVID-19 vaccine tailwinds that could net them each significant profits for their role over the next several years”.
How To Play This “Post-Election Bounce” Trend
Today’s article highlights a group of companies that tend to decline before an election – underperforming the stock market by over one-third as we move towards an election – and then recover.